220 related articles for article (PubMed ID: 27865593)
21. MiR-125b inhibits anaplastic thyroid cancer cell migration and invasion by targeting PIK3CD.
Bu Q; You F; Pan G; Yuan Q; Cui T; Hao L; Zhang J
Biomed Pharmacother; 2017 Apr; 88():443-448. PubMed ID: 28122310
[TBL] [Abstract][Full Text] [Related]
22. CSPG4 Is a Potential Therapeutic Target in Anaplastic Thyroid Cancer.
Egan CE; Stefanova D; Ahmed A; Raja VJ; Thiesmeyer JW; Chen KJ; Greenberg JA; Zhang T; He B; Finnerty BM; Zarnegar R; Jin MM; Scognamiglio T; Dephoure N; Fahey T; Min IM
Thyroid; 2021 Oct; 31(10):1481-1493. PubMed ID: 34078123
[No Abstract] [Full Text] [Related]
23. Establishment and characterization of a new patient-derived anaplastic thyroid cancer cell line (C3948), obtained through fine-needle aspiration cytology.
Pinto AT; Pojo M; Simões-Pereira J; Roque R; Saramago A; Roque L; Martins C; André S; Cabeçadas J; Leite V; Cavaco BM
Endocrine; 2019 Nov; 66(2):288-300. PubMed ID: 31368081
[TBL] [Abstract][Full Text] [Related]
24. TMEM158 May Serve as a Diagnostic Biomarker for Anaplastic Thyroid Carcinoma: An Integrated Bioinformatic Analysis.
Li HN; Du YY; Xu T; Zhang R; Wang G; Lv ZT; Li XR
Curr Med Sci; 2020 Dec; 40(6):1137-1147. PubMed ID: 33428142
[TBL] [Abstract][Full Text] [Related]
25. Targeting CDK12-mediated transcription regulation in anaplastic thyroid carcinoma.
Geng M; Yang Y; Cao X; Dang L; Zhang T; Zhang L
Biochem Biophys Res Commun; 2019 Dec; 520(3):544-550. PubMed ID: 31615655
[TBL] [Abstract][Full Text] [Related]
26. Evolving molecularly targeted therapies for advanced-stage thyroid cancers.
Bible KC; Ryder M
Nat Rev Clin Oncol; 2016 Jul; 13(7):403-16. PubMed ID: 26925962
[TBL] [Abstract][Full Text] [Related]
27. [Molecular diagnostics enable targeted therapies for anaplastic and poorly differentiated thyroid cancer].
Altena R; Nilsson M; Bergman V; Dahlberg J; Christofer Juhlin C; Zedenius J
Lakartidningen; 2024 Feb; 121():. PubMed ID: 38712675
[TBL] [Abstract][Full Text] [Related]
28. Combination of Novel Therapies and New Attempts in Anaplastic Thyroid Cancer.
Li W; Li Y; Li J; Pang H
Technol Cancer Res Treat; 2023; 22():15330338231169870. PubMed ID: 37122242
[TBL] [Abstract][Full Text] [Related]
29. Search for new genetic biomarkers in poorly differentiated and anaplastic thyroid carcinomas using next generation sequencing.
Sykorova V; Dvorakova S; Vcelak J; Vaclavikova E; Halkova T; Kodetova D; Lastuvka P; Betka J; Vlcek P; Reboun M; Katra R; Bendlova B
Anticancer Res; 2015 Apr; 35(4):2029-36. PubMed ID: 25862857
[TBL] [Abstract][Full Text] [Related]
30. Anaplastic thyroid cancer.
Ranganath R; Shah MA; Shah AR
Curr Opin Endocrinol Diabetes Obes; 2015 Oct; 22(5):387-91. PubMed ID: 26313900
[TBL] [Abstract][Full Text] [Related]
31. Aberrant lipid metabolism in anaplastic thyroid carcinoma reveals stearoyl CoA desaturase 1 as a novel therapeutic target.
von Roemeling CA; Marlow LA; Pinkerton AB; Crist A; Miller J; Tun HW; Smallridge RC; Copland JA
J Clin Endocrinol Metab; 2015 May; 100(5):E697-709. PubMed ID: 25675381
[TBL] [Abstract][Full Text] [Related]
32. LncRNA PTCSC3 affects drug resistance of anaplastic thyroid cancer through STAT3/INO80 pathway.
Wang XM; Liu Y; Fan YX; Liu Z; Yuan QL; Jia M; Geng ZS; Gu L; Lu XB
Cancer Biol Ther; 2018 Jul; 19(7):590-597. PubMed ID: 29561707
[TBL] [Abstract][Full Text] [Related]
33. Effects of BP-14, a novel cyclin-dependent kinase inhibitor, on anaplastic thyroid cancer cells.
Allegri L; Baldan F; Mio C; Puppin C; Russo D; Kryštof V; Damante G
Oncol Rep; 2016 Apr; 35(4):2413-8. PubMed ID: 26884249
[TBL] [Abstract][Full Text] [Related]
34. Molecular Pathology of Poorly Differentiated and Anaplastic Thyroid Cancer: What Do Pathologists Need to Know?
Volante M; Lam AK; Papotti M; Tallini G
Endocr Pathol; 2021 Mar; 32(1):63-76. PubMed ID: 33543394
[TBL] [Abstract][Full Text] [Related]
35. Overexpressed in anaplastic thyroid carcinoma-1 (OEATC-1) as a novel gene responsible for anaplastic thyroid carcinoma.
Mizutani K; Onda M; Asaka S; Akaishi J; Miyamoto S; Yoshida A; Nagahama M; Ito K; Emi M
Cancer; 2005 May; 103(9):1785-90. PubMed ID: 15789362
[TBL] [Abstract][Full Text] [Related]
36. Carfilzomib is an effective anticancer agent in anaplastic thyroid cancer.
Mehta A; Zhang L; Boufraqech M; Zhang Y; Patel D; Shen M; Kebebew E
Endocr Relat Cancer; 2015 Jun; 22(3):319-29. PubMed ID: 25972243
[TBL] [Abstract][Full Text] [Related]
37. Down-regulation of transcription elogation factor A (SII) like 4 (TCEAL4) in anaplastic thyroid cancer.
Akaishi J; Onda M; Okamoto J; Miyamoto S; Nagahama M; Ito K; Yoshida A; Shimizu K
BMC Cancer; 2006 Nov; 6():260. PubMed ID: 17076909
[TBL] [Abstract][Full Text] [Related]
38. Metastatic Anaplastic Thyroid Carcinoma in Complete Remission: Morphological, Molecular, and Clinical Work-Up of a Rare Case.
Stenman A; Hellgren LS; Jatta K; Hysek M; Zemmler M; Altena R; Nilsson IL; Bränström R; Zedenius J; Juhlin CC
Endocr Pathol; 2020 Mar; 31(1):77-83. PubMed ID: 32016808
[TBL] [Abstract][Full Text] [Related]
39. Genes and pathways identified in thyroid carcinoma based on bioinformatics analysis.
Yu JW; Mai W; Cui YL; Kong LY
Neoplasma; 2016; 63(4):559-68. PubMed ID: 27268919
[TBL] [Abstract][Full Text] [Related]
40. Epigenetic modifications in poorly differentiated and anaplastic thyroid cancer.
Sasanakietkul T; Murtha TD; Javid M; Korah R; Carling T
Mol Cell Endocrinol; 2018 Jul; 469():23-37. PubMed ID: 28552796
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]